This Program Project seeks to test the hypothese that non-fibrillar aggregated assemblies of amyloid beta (AB), which we have term Abeta-derived active ligands (ADALs), are responsible for triggering processes leading to the glial activation, neuronal plasticity malfunction, synaptic degeneration and cell death in Alzheimer's disease. Extending this hypothesis, it is proposed that particular glial proteins modulate competing Abeta assembly process-to enhance ADAL formation. In this program project we will prepare and characterize ADALs, definign conditions that promote their formation, and we will identify the specific responses activated by ADALs in neurons, glia, mixed cultures and organotypic brain slices. These studies will be coordinated with histochemical studies to establish the relevance of ADALs to AD pathology. The focus of project 1 is the preparation and characterization of ADALs and investigation of conditions reponsible for their formation. We will define optimal in vitro conditions for reproducible formation of ADALs,preparing sufficient quantities for structural, biochemical and biophysical characterization studies, and for investigations of their biological responses in collaboration with Projects 2 and 3. The mechanisms governing ADAL formation will be investigated, with an emphasis on the role played by selected glial co-factor proteins associated wit Abeta in AD. We will extend our studies involving atomic force microscopy (AFM) to provide more detailed analysis of ADAL morphology and distribution, and we will use techniques such as field flow fractionation and native gel electrophoresis for ADAL purification. We will employ laser light scattering, analytical ultracentrifugation and fluroescence polarization and energy transfer techniques to investigate ADAL assembly mechanisms. The major questions to be addressed in this project are: What experimental conditions favor the formation of ADALs and what techniques enable the isolation of homogeneous preparation of ADAL structures? What factors govern the formation of different ADAL structures, and inactive fibrillar or soluble Abeta assemblies? What are the biochemical and biophysical characteristics of ADALs? What specific features of the Abeta 1-42 primary structure are important for assembly into different ADAL and fibrillar structures? What amino acid residues are important for the biological activity of ADALs in neurons? in glia? The integration of these studies with the extensive biological capabilities within this Program Project will define the molecular and cellular processes that lead to the inflammatory pathology, synaptic degeneration and neuronal cell death that occurs in Alzheimer's disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG015501-02
Application #
6098812
Study Section
Project Start
1998-09-30
Project End
1999-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Evanston Hospital
Department
Type
DUNS #
City
Evanston
State
IL
Country
United States
Zip Code
60201
Stine Jr, W Blaine; Dahlgren, Karie N; Krafft, Grant A et al. (2003) In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 278:11612-22
Gong, Yuesong; Chang, Lei; Viola, Kirsten L et al. (2003) Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 100:10417-22
Chromy, Brett A; Nowak, Richard J; Lambert, Mary P et al. (2003) Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 42:12749-60
Wang, Hai-Wei; Pasternak, Joseph F; Kuo, Helen et al. (2002) Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924:133-40
Van Eldik, Linda J; Koppal, Tanuja; Watterson, D Martin (2002) Barriers to Alzheimer disease drug discovery and development in academia. Alzheimer Dis Assoc Disord 16 Suppl 1:S18-28
Sheng, J G; Jones, R A; Zhou, X Q et al. (2001) Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation. Neurochem Int 39:341-8
Klein, W L; Krafft, G A; Finch, C E (2001) Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 24:219-24
Guo, L; Sawkar, A; Zasadzki, M et al. (2001) Similar activation of glial cultures from different rat brain regions by neuroinflammatory stimuli and downregulation of the activation by a new class of small molecule ligands. Neurobiol Aging 22:975-81
Koppal, T; Lam, A G; Guo, L et al. (2001) S100B proteins that lack one or both cysteine residues can induce inflammatory responses in astrocytes and microglia. Neurochem Int 39:401-7
Peskind, E R; Griffin, W S; Akama, K T et al. (2001) Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int 39:409-13

Showing the most recent 10 out of 20 publications